Peptides by condition · Weight, blood sugar, liver and gut
Peptides studied for HIV lipodystrophy
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 7 study pages on HIV lipodystrophy: 7 in people (all meta-analyses or randomized trials). They studied one compound, Tesamorelin.
What the research on HIV lipodystrophy looks like
Some people living with HIV build up deep belly fat around the organs, a change called HIV-associated lipodystrophy that was tied to older HIV medicines. That fat, called visceral fat, carries risks for the heart and liver beyond how it looks. The peptide research on it centers on tesamorelin, a copy of GHRH, the brain hormone that tells the pituitary gland to release growth hormone. Growth hormone in turn breaks down stored fat, and deep belly fat responds to it more than the fat under the skin.
These trials measure visceral fat on a CT scan across the belly, in square centimeters, against placebo over about six months to a year. Some also measured liver fat, blood sugar, blood fats and the muscles of the trunk, and one extension switched people off the drug to see whether the change lasted.
The studies were in adults with HIV on their HIV medicines and with extra belly fat, so the results describe that group. Watch what happened to the fat after people stopped, and to blood sugar while they were on it. A change on a scan is a measured change in fat, not proof of fewer heart attacks or liver problems, which these trials were not built to count.

Model. Individual results vary.
The 7 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Tesamorelin
7 in peopleFor HIV lipodystrophy, 7 of our study pages are filed under Tesamorelin: 1 meta-analysis and 6 randomized trials in people. The largest in people enrolled 806 people and was published in 2010. They were published from 2007 to 2026, in Obes Res Clin Pract, J Clin Endocrinol Metab, N Engl J Med, J Acquir Immune Defic Syndr, JAMA, J Frailty Aging and AIDS.
FDA-approved, with a use tied to HIV lipodystrophy on its label: Egrifta (injection) for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss).
- Meta-analysis in people · 2026Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy
- Randomized trial in people · 806 people · 2010Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeks
- Randomized trial in people · 412 people · 2007Tesamorelin: 15.2% drop in visceral fat at 26 weeks in HIV
- Randomized trial in people · 404 people · 2010Tesamorelin: 10.9% less visceral fat at 6 months in HIV patients
- Randomized trial in people · 50 people · 2014Tesamorelin cut visceral and liver fat over 6 months in HIV patients
- Randomized trial in people · 2019Tesamorelin: denser, larger trunk muscles at 26 weeks in HIV
- Randomized trial in people · 2008Tesamorelin: visceral fat down 18% over 52 weeks in HIV patients
Side by side
For the compound on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Tesamorelin | 7 | 0 | 806 | Approved, a use tied to it |
- In people
- 7
- Animals or cells
- 0
- Largest in people
- 806
- FDA
- Approved, a use tied to it
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyIt pools only a handful of trials, all in adults with HIV, so it does not show how tesamorelin works in people without HIV. BMI and subcutaneous fat did not change, so the effect was on specific fat stores rather than on BMI.
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksThe placebo comparison lasted only 26 weeks; the 52-week results compare one group with its own starting point, not with placebo. Everyone studied had HIV and was on ART, so it does not show effects in other people.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for HIV lipodystrophy?
Our 7 study pages on HIV lipodystrophy are all filed under one compound, Tesamorelin.
Have any been tested in people with HIV lipodystrophy?
Yes: all 7 were in people, all of them meta-analyses or randomized trials (Tesamorelin). The largest enrolled 806 people: “Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeks” (2010).
Is any peptide FDA-approved for HIV lipodystrophy?
Yes, with a use tied to HIV lipodystrophy on their FDA labels: Tesamorelin as Egrifta. Every compound here is.
How large were the studies in people on HIV lipodystrophy?
Of the 7 in people, 4 give their size on our pages: 3 had 100 to 999 and 1 had fewer than 100. The largest, a randomized trial from 2010, enrolled 806.
What is the newest study on HIV lipodystrophy here?
Of our study pages on HIV lipodystrophy, the newest is “Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy”, a meta-analysis in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.